AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hor ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ:AZN) said on Friday that Enhertu received European Union approval for the treatment of adults with advanced metastatic breast cancer. Enhertu is ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

chemotherapy in HR+, HER2-low metastatic breast cancer patients. AstraZeneca owes Daiichi Sankyo a $125 million milestone payment after the EU approval of Enhertu for certain breast cancer patients.

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a ...

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Tuesday said Datroway has secured EU approval to treat breast cancer patients. Daiichi Sankyo, a Tokyo-based pharmaceutical company, and ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...